-
公开(公告)号：US20100179128A1
公开(公告)日：2010-07-15
申请号：US12063432
申请日：2006-08-08
申请人： Richard Jonathan Daniel Hatley , Jag Paul Heer , John Liddle , Andrew McMurtrie Mason , Ivan Leo Pinto , Shahzad Sharooq Rahman , Ian Edward David Smith
发明人： Richard Jonathan Daniel Hatley , Jag Paul Heer , John Liddle , Andrew McMurtrie Mason , Ivan Leo Pinto , Shahzad Sharooq Rahman , Ian Edward David Smith
IPC分类号： A61K31/55 , C07D473/04 , A61K31/522 , C07D519/00 , A61K31/5377 , A61P3/06 , A61P3/10 , A61P3/04 , A61P9/04 , A61P9/10 , A61P7/02 , A61P13/12
CPC分类号： C07D473/04 , C07D473/06
摘要： The present invention relates to compounds of formula (I) which are xanthine derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing these active compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial
摘要翻译： 本发明涉及作为黄嘌呤衍生物的式（I）化合物，制备所述衍生物的方法，含有这些活性化合物的药物制剂，以及该化合物在治疗中的用途，例如， HM74A受体的激活有助于该疾病或受体活化将是有益的
-
公开(公告)号：US08143264B2
公开(公告)日：2012-03-27
申请号：US12063434
申请日：2006-08-08
IPC分类号： C07D473/04 , C07D473/06 , A61K31/522 , A61P9/10 , A61P9/00 , A61P13/12 , A61P3/10
CPC分类号： C07D473/04 , C07D473/06
摘要： The present invention relates to a xanthine compound derivative which is 3-butyl-8-chloro-1-(3-{5-[(4-fluorophenyl)methyl]-2H-tetrazol-2-yl}propyl)-3,7-dihydro-1H-purine-2,6-dione: a pharmaceutically acceptable salt thereof, corresponding pharmaceutical formulations, combinations, preparation methods and methods or uses in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
摘要翻译： 本发明涉及3-丁基-8-氯-1-（3- {5 - [（4-氟苯基）甲基] -2H-四唑-2-基}丙基）-3,7 - 二氢-1H-嘌呤-2,6-二酮：其药学上可接受的盐，相应的药物制剂，组合，制备方法和方法或用途，用于治疗HM74A受体的未激活有助于疾病或其中激活的疾病 的受体将是有益的。
-
公开(公告)号：US20100168122A1
公开(公告)日：2010-07-01
申请号：US12063434
申请日：2006-08-08
IPC分类号： C07D473/04 , A61K31/522
CPC分类号： C07D473/04 , C07D473/06
摘要： The present invention relates to compounds of formula (I) which are xanthine derivatives, processes for manufacture of said derivatives, pharmaceutical formulations containing these compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial
摘要翻译： 本发明涉及作为黄嘌呤衍生物的式（I）化合物，所述衍生物的制备方法，含有这些化合物的药物制剂以及该化合物在治疗中的用途，例如治疗未激活的疾病 HM74A受体有助于该疾病或受体活化将是有益的
-
公开(公告)号：US20110257205A1
公开(公告)日：2011-10-20
申请号：US13088962
申请日：2011-04-18
CPC分类号： C07D473/04 , C07D473/06
摘要： The present invention relates to compounds which are xanthine derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing these compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
摘要翻译： 本发明涉及作为黄嘌呤衍生物的化合物，用于制备所述衍生物的方法，含有这些化合物的药物制剂以及该化合物在治疗中的用途，例如用于治疗HM74A受体活化不足的疾病 对于该疾病或受体的激活将是有益的。
-
5.发明申请Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia 审中-公开邻氨基苯甲酸衍生物及其在治疗脂质代谢疾病中的应用，特别是血脂异常公开(公告)号：US20080139565A1
公开(公告)日：2008-06-12
申请号：US11815349
申请日：2006-02-14
IPC分类号： A61K31/4965 , C07D241/04 , C07D403/04 , A61K31/53 , A61P9/10 , C07D253/10 , A61K31/497
CPC分类号： C07D241/44 , C07D215/12 , C07D217/22 , C07D253/10 , C07D277/82 , C07D285/08 , C07D295/215 , C07D333/66
摘要： Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2, W, Y and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which activation of the receptor will be beneficial, are disclosed.
摘要翻译： 式（I）的其中R 1，R 2，W，Y和Z的治疗活性的邻氨基苯甲酸衍生物如说明书中所定义，用于制备所述衍生物的方法 公开了含有活性化合物的药物制剂和该药物在治疗中的用途，特别是用于治疗其中HM74A受体的未激活有助于疾病或受体活化将是有益的疾病。
-
公开(公告)号：US20080221108A1
公开(公告)日：2008-09-11
申请号：US11815350
申请日：2006-02-14
IPC分类号： A61K31/196 , C07D271/06 , C07D253/10 , A61K31/4245 , A61P3/00 , A61P9/10 , A61K31/53 , C07C63/06
CPC分类号： C07C235/24 , C07D253/10 , C07D271/06 , C07D401/04
摘要： Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2 and W, are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which activation of the receptor will be beneficial, are disclosed.
摘要翻译： 其中R 1，R 2和W的式（I）的治疗活性的邻氨基苯甲酸衍生物如说明书中所定义，用于制备所述衍生物，药物制剂 含有活性化合物和化合物在治疗中的用途，特别是在治疗其中HM74A受体的活化不足有助于疾病或其中受体的活化将是有益的疾病方面。
-
公开(公告)号：US20080214638A1
公开(公告)日：2008-09-04
申请号：US11815402
申请日：2006-02-14
IPC分类号： A61K31/41 , C07C229/00 , A61K31/19 , A61P29/00 , A61P9/00 , C07D257/04
CPC分类号： C07D257/04 , C07C235/24
摘要： Therapeutically active anthranilic acid derivatives of Formula (I) or of Formula (Ia) wherein R, R1, R2 and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which activation of the receptor will be beneficial, are disclosed.
摘要翻译： 式（I）或式（Ia）的其中R，R 1，R 2和Z如本说明书中所定义的式（I）或式（Ia）的治疗活性的邻氨基苯甲酸衍生物 所述衍生物的制备，含有活性化合物的药物制剂和该化合物在治疗中的用途，特别是用于治疗HM74A受体的未激活有助于疾病或受体激活将是有益的疾病， 被披露。
-
公开(公告)号：US20090247541A1
公开(公告)日：2009-10-01
申请号：US12480182
申请日：2009-06-08
IPC分类号： A61K31/496 , C07D401/06 , A61P15/10 , A61P15/06 , A61P15/00
CPC分类号： A61K31/5377 , C07D401/06 , C07D413/14
摘要： Compounds of formula (I) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
摘要翻译： 式（I）的化合物，其中R 1是2-茚满基，R 2是1-甲基丙基，R 3是选自2,6-二甲基-3-吡啶基或4,6-二甲基-3-吡啶基的基团，R 4表示甲基和R 5 表示氢或甲基，或者R4和R5与它们所连接的氮原子一起代表吗啉代及其药学上可接受的衍生物，其制备方法，含有它们的药物组合物及其在药物中的用途，特别是其用作 催产素拮抗剂。
-
公开(公告)号：US07288564B2
公开(公告)日：2007-10-30
申请号：US10450894
申请日：2001-12-20
申请人： Derek Anthony Demaine , Gerard Martin Paul Giblin , Rachel Elizabeth Hosking , Graham George Adam Inglis , Xiao Qing Lewell , Simon John Fawcett MacDonald , Andrew McMurtrie Mason , Martin Edward Swarbrick
发明人： Derek Anthony Demaine , Gerard Martin Paul Giblin , Rachel Elizabeth Hosking , Graham George Adam Inglis , Xiao Qing Lewell , Simon John Fawcett MacDonald , Andrew McMurtrie Mason , Martin Edward Swarbrick
IPC分类号： A61K31/404 , C07D209/04
CPC分类号： C07D407/04 , C07D209/18 , C07D409/04
摘要： Compounds of formula (I) or salts or solvates thereof or physiologically functional derivatives thereof are potent binders at the EP4 receptor and are of use in the treatment or prevention of conditions such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.
摘要翻译： 式（I）化合物或其盐或溶剂合物或其生理功能衍生物是EP4受体的有效结合剂，并且可用于治疗或预防诸如疼痛，炎症，免疫学，骨骼，神经变性或肾脏疾病的病症。
-
公开(公告)号：US08367673B2
公开(公告)日：2013-02-05
申请号：US12412837
申请日：2009-03-27
申请人： Alan David Borthwick , Richard Jonathan Hatley , Deirdre Mary Bernadette Hickey , John Liddle , David George Hubert Livermore , Andrew McMurtrie Mason , Neil Derek Miller , Fabrizio Nerozzi , Steven Leslie Sollis , Anna Katrin Szardenings , Paul Graham Wyatt
发明人： Alan David Borthwick , Richard Jonathan Hatley , Deirdre Mary Bernadette Hickey , John Liddle , David George Hubert Livermore , Andrew McMurtrie Mason , Neil Derek Miller , Fabrizio Nerozzi , Steven Leslie Sollis , Anna Katrin Szardenings , Paul Graham Wyatt
IPC分类号： A61K31/497 , A61K31/4965
CPC分类号： C07D241/08 , A61K38/00 , C07D401/10 , C07D403/06 , C07D413/10 , C07D417/06 , C07K5/06078 , C07K5/06191
摘要： A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译： 一种治疗或预防通过催产素作用介导的疾病或病症的方法，其包括向有需要的人施用有效量的式（I）化合物或其药学上可接受的盐。
-
-
-
-
-
-
-
-
-
搜索结果
33 条记录 (耗时 0.037 秒)
